Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Acquires 9,920 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov acquired 9,920 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were bought at an average cost of $17.86 per share, for a total transaction of $177,171.20. Following the acquisition, the director directly owned 25,000 shares in the company, valued at $446,500. This represents a 65.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

George Pavlov also recently made the following trade(s):

• On Thursday, February 19th, George Pavlov acquired 4,422 shares of Maplight Therapeutics stock. The shares were acquired at an average cost of $17.57 per share, with a total value of $77,694.54.
• On Wednesday, February 18th, George Pavlov purchased 10,658 shares of Maplight Therapeutics stock. The stock was acquired at an average cost of $17.48 per share, for a total transaction of $186,301.84.

Maplight Therapeutics Stock Down 0.2%

NASDAQ MPLT opened at $17.88 on Friday. The stock has a market capitalization of $811.22 million and a P/E ratio of -0.48. The company’s 50-day moving average price is $17.93. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MPLT shares. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Leerink Partners assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price for the company. Jefferies Financial Group initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $49,168,000. Invesco Ltd. acquired a new position in Maplight Therapeutics in the fourth quarter valued at $228,000. Vestal Point Capital LP purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $6,763,000. Tudor Investment Corp ET AL acquired a new position in Maplight Therapeutics during the fourth quarter valued at approximately $840,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Maplight Therapeutics in the 4th quarter valued at $952,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.